Medicenna Therapeutics (MDNA) Emerging Growth Conference 82 summary

Program highlights and pipeline overview

• Focus on engineered cytokines (superkines) for cancer and autoimmune diseases, leveraging Nobel Prize-winning technology.

• Lead asset MDNA-11, an IL-2 superagonist, is in phase I/II trials, showing 30%-50% response rates in patients who failed checkpoint inhibitors.

• Additional programs include a phase III-ready IL-4 superkine for glioblastoma and a bispecific anti-PD-1 (MDNA-113) targeting cold tumors.

• Pipeline covers early, mid, and late-stage assets, with multiple upcoming data readouts and milestones expected in the next two quarters.

• Healthy cash position supports operations into Q3 next year, with several catalysts anticipated before year-end.

Clinical data and trial results

• MDNA-11 demonstrates durable responses, including complete tumor disappearance in some cases, and a favorable safety profile with mostly mild, short-duration adverse events.

• Combination studies with Keytruda show similar efficacy and safety, with response rates of 30%-50% in difficult-to-treat tumor types.

• Accelerated approval pathways are possible for certain biomarker-driven tumors, with benchmarks of 20%-30% response rates.

• MDNA-11’s unique design selectively stimulates cancer-fighting immune cells while minimizing toxicity and regulatory T cell activation.

• Once-every-two-weeks dosing is a significant improvement over legacy IL-2 therapies.

Industry context and strategic outlook

• Bispecific checkpoint inhibitors are a major industry focus, with recent multi-billion dollar deals highlighting the value of this approach.

• MDNA-113 combines anti-PD-1, IL-2, and IL-13 for tumor-targeted activation, aiming to address cold tumors unresponsive to current therapies.

• The company is seeking partnerships for its glioblastoma program and preparing MDNA-113 for IND-enabling studies by year-end.

• Strong interest and positive reception at major conferences, with big pharma engagement and anticipation for upcoming data.

• Multiple analyst coverages and insider ownership support confidence in the company’s direction.